TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07586124: A Multicenter, Randomized, Double-Blind, Phase II Clinical Study of Pucotenlimab Injection Combined With Becotatug Vedotin for Injection as Perioperative Therapy in Participants With Locally Advanced Resectable Head and

Sponsor: Lepu Biopharma Co., Ltd. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 80 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$8,778,000

Rescue Site Savings

+$5,775,000

Unlock Full NCT07586124 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07586124 Rescue Dossier →